Prostate cancer treatment has radically changed over ... are licensed for use in the post-docetaxel setting. In the absence of an evidence base on optimum sequencing, clinical experience suggests ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

Analyses found lower cardiotoxicity from triplet mHSPC therapy involving darolutamide vs abiraterone/prednisone in addition to ADT and docetaxel. Triplet therapy ...

prostate cancer and non-small cell lung cancer either alone or with other medications. It belongs to taxane group. It stops the growth and spread of cancer cells. When should Docetaxel not be taken?

Prostate cancer accounts for 3.8% of total cancer-related deaths worldwide. The combination of docetaxel and androgen deprivation therapy is useful in the management of the disease, but unfortunately, ...